Short Interest in BioStem Technologies, Inc. (OTCMKTS:BSEM) Rises By 22.3%

BioStem Technologies, Inc. (OTCMKTS:BSEM) was the target of a significant growth in short interest in October. As of October 31st, there was short interest totalling 115,100 shares, a growth of 22.3% from the October 15th total of 94,100 shares. Based on an average trading volume of 124,800 shares, the short-interest ratio is currently 0.9 days.

BioStem Technologies Price Performance

OTCMKTS:BSEM traded down 3.51 during mid-day trading on Friday, hitting 13.90. 259,200 shares of the company’s stock were exchanged, compared to its average volume of 34,615. BioStem Technologies has a one year low of 2.34 and a one year high of 28.26. The business has a fifty day moving average price of 13.52 and a 200 day moving average price of 10.72. The company has a market cap of $231.00 million, a PE ratio of 20.44 and a beta of -0.36.

BioStem Technologies (OTCMKTS:BSEM) last posted its quarterly earnings data on Tuesday, November 12th. The company reported 0.32 EPS for the quarter, topping the consensus estimate of 0.31 by 0.01. The business had revenue of 82.56 million for the quarter, compared to the consensus estimate of 78.22 million. On average, equities analysts forecast that BioStem Technologies will post 1.13 EPS for the current fiscal year.

BioStem Technologies Company Profile

BioStem Technologies, Inc, a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases.